Dr. Niels Prins was interviewed by the Volkskrant about the study with the drug Aducanumab:
“After years of fruitless research, it appears that a drug has been developed that can slow down Alzheimer’s disease, although the effect is modest. On Thursday evening, the American pharmaceutical company Biogen announced the long-awaited results of a large international study. The results show that a high dose of the drug aducanumab slows the progression of patients and reduces protein accumulations in the brain.
The effects are small but significant, said American neurologists at the press conference in San Diego, which was broadcast live. ‘Alzheimer is associated with a loss of autonomy; addressing this loss is the key,’ said Canadian neurologist Sharon Cohen, one of the study leaders. ‘An encouraging result,’ said neurologist Niels Prins by telephone from San Diego. Prins is director of the Brain Research Center in Amsterdam, where 34 patients participated in the study. ‘For the first time, there is a drug that not only affects the disease mechanism but also the daily practice.’ In patients, the aggregation of amyloid proteins in the brain decreased and the accumulation of tau protein did not increase as quickly. This had consequences for their functioning, as was shown by four different tests.”
Read the full article here: https://www.volkskrant.nl/nieuws-achtergrond/medicijn-vertraagt-achteruitgang-door-alzheimer~b4e901f8/